Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

CLLS

Cellectis ADR

Last Close
May 16 • 04:00PM ET
3.04
Dollar change
-0.02
Percentage change
-0.66 		%
Scroll to Statements
Index- P/E- EPS (ttm)-1.69 Insider Own3.93% Shs Outstand71.75M Perf Week-6.18%
Market Cap218.11M Forward P/E- EPS next Y-0.52 Insider Trans0.00% Shs Float68.93M Perf Month23.57%
Income-101.07M PEG- EPS next Q-0.33 Inst Own13.77% Short Float0.95% Perf Quarter6.66%
Sales0.76M P/S286.99 EPS this Y32.66% Inst Trans-2.50% Short Ratio12.09 Perf Half Y18.75%
Book/sh1.18 P/B2.58 EPS next Y56.80% ROA-36.78% Short Interest0.66M Perf Year73.71%
Cash/sh2.84 P/C1.07 EPS next 5Y- ROE-108.06% 52W Range0.96 - 3.77 Perf YTD-1.30%
Dividend Est.- P/FCF- EPS past 5Y1.69% ROI-61.67% 52W High-19.44% Beta3.11
Dividend TTM- Quick Ratio1.50 Sales past 5Y42.86% Gross Margin-2447.28% 52W Low215.74% ATR (14)0.19
Dividend Ex-Date- Current Ratio1.50 EPS Y/Y TTM27.56% Oper. Margin-14232.10% RSI (14)57.38 Volatility4.52% 6.36%
Employees221 Debt/Eq1.10 Sales Y/Y TTM-96.09% Profit Margin-13386.23% Recom2.20 Target Price6.20
Option/ShortYes / Yes LT Debt/Eq0.94 EPS Q/Q-1.70% Payout- Rel Volume0.28 Prev Close3.06
Sales Surprise10.56% EPS Surprise-228.21% Sales Q/Q-98.23% EarningsApr 29 AMC Avg Volume54.27K Price3.04
SMA207.93% SMA5013.28% SMA20024.74% Trades Volume15,243 Change-0.66%
Date Action Analyst Rating Change Price Target Change
Mar-17-23Initiated Bryan Garnier Buy $6
May-18-22Upgrade Robert W. Baird Neutral → Outperform $10
Jan-06-22Downgrade Wells Fargo Overweight → Equal Weight $39 → $16
Nov-30-21Initiated JMP Securities Mkt Outperform $20
Nov-08-21Downgrade William Blair Outperform → Mkt Perform
Oct-08-21Downgrade Robert W. Baird Outperform → Neutral $39 → $10
Apr-28-21Downgrade Guggenheim Buy → Neutral
Mar-16-21Upgrade Robert W. Baird Neutral → Outperform $23 → $39
Aug-19-20Upgrade Citigroup Neutral → Buy $15 → $32
May-12-20Initiated Robert W. Baird Outperform $20
Show Previous Ratings
May-16-24 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire)
May-06-24 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire) +12.04%
04:22AM
Cellectis Secures $140 Million Additional Equity Investment From AstraZeneca
(MT Newswires)
02:00AM
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
(GlobeNewswire)
May-03-24 06:10AM
Cellectis CFO Bing Wang Retires, Interim CFO Appointed
(MT Newswires)
04:30PM Loading…
May-02-24 04:30PM
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
(GlobeNewswire) +17.90%
Apr-29-24 10:53PM
CLLS Stock Earnings: Cellectis Misses EPS, Misses Revenue for Q4 2023
(InvestorPlace)
04:46PM
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
(GlobeNewswire)
Apr-22-24 04:30PM
Cellectis Presents Novel TALEN Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
(GlobeNewswire)
Apr-10-24 04:30PM
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
(GlobeNewswire)
Apr-08-24 04:30PM
Cellectis Announces Two Poster Presentations on Novel TALEN Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
(GlobeNewswire)
Apr-04-24 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire)
Mar-04-24 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire)
Feb-02-24 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire)
Jan-16-24 04:30PM
Cellectis announces the drawdown of the second tranche of 15 million under the credit facility agreement entered with the European Investment Bank (EIB)
(GlobeNewswire)
04:30PM Loading…
Jan-08-24 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire)
Dec-22-23 04:30PM
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
(GlobeNewswire)
Dec-01-23 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire)
Nov-17-23 04:30PM
Cellectis' Shareholders Meeting to be Held on December 22, 2023
(GlobeNewswire) +11.83%
Nov-15-23 02:30AM
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
(GlobeNewswire) +9.38%
Nov-06-23 04:30PM
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
(GlobeNewswire)
Nov-03-23 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire)
Nov-02-23 04:30PM
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
(GlobeNewswire) +14.02%
Nov-01-23 04:30PM
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
(GlobeNewswire) +172.16%
08:13AM
Why Is Cellectis (CLLS) Stock Up 175% Today?
(InvestorPlace)
08:02AM
AstraZeneca takes 22% stake in Cellectis as part of collab for 10 cell and gene therapies
(FierceBiotech.com)
03:00AM
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
(GlobeNewswire)
Oct-31-23 04:30PM
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
(GlobeNewswire)
Oct-24-23 04:30PM
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
(GlobeNewswire) -12.50%
Oct-12-23 04:30PM
Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Syndrome Type 1 (APDS1)
(GlobeNewswire)
04:30PM Loading…
Oct-03-23 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire)
09:55AM
These 2 Strong Buy Penny Stocks Could Gain Over 500%, Says Baird
(TipRanks)
Sep-27-23 04:30PM
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
(GlobeNewswire)
Sep-05-23 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire) -8.96%
Aug-07-23 04:30PM
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
(GlobeNewswire)
Aug-03-23 04:30PM
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
(GlobeNewswire)
Aug-01-23 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire) -6.07%
Jul-27-23 04:30PM
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
(GlobeNewswire)
Jul-12-23 04:30PM
Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
(GlobeNewswire) +6.02%
Jun-28-23 04:30PM
Cellectis S.A. Reports Results from Annual Shareholders General Meeting Held on June 27, 2023
(GlobeNewswire)
Jun-13-23 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire)
Jun-09-23 04:30PM
Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023
(GlobeNewswire)
Jun-05-23 04:30PM
Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event
(GlobeNewswire)
May-31-23 04:50PM
Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
(GlobeNewswire)
May-17-23 04:30PM
Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
(GlobeNewswire)
May-12-23 01:30AM
Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
(GlobeNewswire)
May-11-23 10:20AM
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
(GlobeNewswire) -5.73%
May-10-23 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire)
May-04-23 04:30PM
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
(GlobeNewswire)
May-02-23 04:35PM
Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
(GlobeNewswire) -6.41%
Apr-27-23 04:30PM
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
(GlobeNewswire)
Apr-24-23 04:30PM
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofis Alemtuzumab
(GlobeNewswire)
Apr-17-23 02:00AM
Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
(GlobeNewswire)
Apr-12-23 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire)
Apr-11-23 04:30PM
Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22
(GlobeNewswire)
Apr-04-23 04:30PM
Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of 20 million
(GlobeNewswire)
Mar-15-23 05:02PM
Monthly information on share capital and company voting rights
(GlobeNewswire) -7.58%
Mar-14-23 05:00PM
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
(GlobeNewswire)
Mar-08-23 04:45PM
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
(GlobeNewswire)
Mar-06-23 04:30PM
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
(GlobeNewswire)
Mar-01-23 04:30PM
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
(GlobeNewswire)
Feb-09-23 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire)
Feb-07-23 07:01PM
Cellectis Announces Closing of Global Offering and Exercise of Underwriters Option to Purchase Additional Shares
(GlobeNewswire)
Feb-03-23 09:33AM
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
(GlobeNewswire) -23.01%
12:48AM
Cellectis Announces Pricing of Follow-On Offering
(GlobeNewswire)
Feb-02-23 04:01PM
Cellectis Announces Launch of Follow-On Offering
(GlobeNewswire) +5.16%
Jan-30-23 07:10PM
7 CRISPR Stocks With the Best Long-Term Potential
(InvestorPlace)
Jan-20-23 04:30PM
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
(GlobeNewswire)
Jan-17-23 07:10AM
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
(GlobeNewswire) -11.98%
Jan-09-23 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire) +18.73%
Jan-04-23 05:08PM
Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq
(GlobeNewswire)
Dec-29-22 04:30PM
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
(GlobeNewswire) +5.41%
Dec-28-22 04:30PM
Cellectis secures a 40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
(GlobeNewswire)
Dec-22-22 04:30PM
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
(GlobeNewswire)
Dec-16-22 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire) -9.78%
Dec-13-22 01:47PM
Cellectis Touts Positive Preliminary Data From Two Leukemia Trials
(Benzinga)
07:30AM
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
(GlobeNewswire)
Dec-01-22 04:40PM
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
(GlobeNewswire)
Nov-10-22 09:05AM
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
(GlobeNewswire) +12.56%
02:48AM
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
(GlobeNewswire)
Nov-08-22 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire)
Nov-04-22 12:31PM
Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil
(Zacks)
Nov-03-22 04:36PM
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022
(GlobeNewswire)
04:05PM
Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022
(GlobeNewswire)
Oct-27-22 04:37PM
Cellectis to Report Third Quarter 2022 Financial Results
(GlobeNewswire)
Oct-11-22 04:30PM
Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022
(GlobeNewswire)
Oct-10-22 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire) -5.24%
Oct-05-22 09:45AM
Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy
(Zacks)
Sep-28-22 04:23PM
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
(GlobeNewswire)
Sep-19-22 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire)
Sep-01-22 04:44PM
Cellectis Announces Participation in Four Upcoming Investor Conferences in September
(GlobeNewswire) -6.04%
Aug-22-22 04:30PM
Monthly information on share capital and company voting rights
(GlobeNewswire) -7.02%
Aug-05-22 12:13PM
Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track
(Zacks) +10.90%
Aug-04-22 04:30PM
Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022
(GlobeNewswire) -6.02%
Aug-01-22 04:30PM
Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies
(GlobeNewswire) +14.50%
Jul-28-22 04:30PM
Cellectis to Report Second Quarter 2022 Financial Results
(GlobeNewswire)
Jul-20-22 07:53AM
Strength Seen in Immatics (IMTX): Can Its 18% Jump Turn into More Strength?
(Zacks) +5.19%
Jun-30-22 05:19AM
Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence
(GlobeNewswire)
Jun-28-22 04:36PM
Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors
(GlobeNewswire) -9.35%
04:08PM
Cellectis S.A. Reports Results from Annual Shareholders General Meeting Held on June 28, 2022
(GlobeNewswire)
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and Andre Choulika on February 20, 1999 and is headquartered in Paris, France.
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.